Quantum Pharmaceutical is the UK’s trusted manufacturer and supplier of unlicensed medicines and hard-to-source products.

Investment type
  • Management buyout
Deal value


Exit type
  • IPO
Exit date

December 2014

Exit value


The Team
LDC Team
Quote mark

LDC has been an extremely supportive partner over the past five years in providing the necessary investment to deliver a number of strategic acquisitions and provide transformative change to our facilities and product offering.”

Andrew Scaife, Former Chief Executive Officer
Quantum Pharmaceutical

Successful flotation

In December 2014, Quantum successfully underwent an IPO, which valued the firm at £130m. Following the IPO, LDC retained an 8.2 per cent equity stake, with directors and senior management of Quantum Pharma retaining approximately 8.5 per cent of the issued share capital.

We were keen to remain a part of the team given the promising growth prospects of the new business thanks to its newly licensed Colonis products and the desire of the management team to retain a material stake.

The flotation supported Quantum’s strategy to develop its product base and range across its five core business units in Quantum Pharmaceutical, U L Medicines, Colonis Pharma, Biodose and Quantum Aseptics.


Deal of the Year

Quantum Pharma – Insider Yorkshire Dealmaker Awards

Deal of the Year

Quantum Pharma – Insider North East Dealmaker Awards